# An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.

- **DOI:** [10.1016/s0140-6736(22)02406-0](https://doi.org/10.1016/s0140-6736(22)02406-0)
- **Rating:** Strong (3.8 out of 5)
- **Verdict:** Oral sebetralstat delays rescue treatment and accelerates symptom relief in a blinded phase 2 trial, but complete-case analysis limits certainty.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-03
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fs0140-6736(22)02406-0

## Key claims

1. Time to use of conventional treatment within 12 h of study drug administration was significantly longer with sebetralstat versus placebo
   - Support: Supported
   - Type: Primary finding
   - Basis: prespecified blinded crossover comparison limited by complete-pair analysis and a participant-driven rescue endpoint
   - Location: Abstract; Results; Table 2
2. Sebetralstat was associated with significantly faster symptom relief, as assessed by the Patient Global Impression of Change, than placebo
   - Support: Supported
   - Type: Secondary
   - Basis: blinded patient-reported comparison in complete pairs, with no stated multiplicity control for secondary endpoints
   - Location: Research in context; Results; Table 2
3. There were no serious adverse events or adverse event-related discontinuations.
   - Support: Supported
   - Type: Secondary
   - Basis: systematic safety collection in 68 participants with limited single-dose exposure
   - Location: Abstract; Results; Table 3
4. In a subset of participants (n=6), plasma samples obtained from 15 min to 4 h after study drug administration had near-complete protection from ex vivo stimulated generation of plasma kallikrein and cleavage of high-molecular-weight kininogen.
   - Support: Tentative
   - Type: Secondary
   - Basis: uncontrolled ex vivo pharmacodynamic evidence from only six participants
   - Location: Abstract; Results; Figure 2

## Strengths

- **Randomized evidence for oral attack treatment** The study tests a self-administered oral option against placebo rather than relying on pharmacology alone. This directly extends the prior parenteral on-demand treatment evidence base.
  - Dimension: contribution
  - Location: Research in context; Table 2
- **Masked crossover comparison with systematic safety** Independent sequence generation and identical-looking kits support the blinded within-participant comparison. Adverse events are systematically coded and reported with exposure denominators.
  - Dimension: methodological rigour
  - Location: Methods, Randomisation and masking and Procedures; Table 3
- **Clinical context informs subsequent trial design** The Discussion examines abdominal involvement and treatment delays, then identifies concrete phase 3 changes including broader attack eligibility and additional dose evaluation.
  - Dimension: positioning
  - Location: Discussion, abdominal attacks and phase 3 design changes

## Limitations

- **Complete-pair analysis leaves missing-data uncertainty unresolved** Only 53 of 68 randomized participants enter the efficacy analysis, without a sensitivity analysis for incomplete pairs. Administrative withdrawal explains most exclusions but does not establish that their omission is inconsequential.
  - Dimension: methodological rigour
  - Location: Statistical analysis; Results, participant disposition
- **Secondary findings lack stated multiplicity control** Numerous secondary and exploratory comparisons are reported without described multiplicity adjustment. The six-person pharmacodynamic subset and unshown carryover analyses further limit verification of supporting evidence.
  - Dimension: methodological rigour
  - Location: Methods, Outcomes and Statistical analysis; Results; Figure 2; Table 2
- **Selected participants and attacks constrain generalization** Enrollment was entirely White and excluded prophylactic treatment, while facial and laryngeal attacks were ineligible. Physician validation before dosing also limits direct transfer to unrestricted home use.
  - Dimension: application pathway
  - Location: Methods, Study design and participants and Procedures; Table 1

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. 2 reported values do not reconcile, but the key claims do not rest on them.
  - Minor reporting notes (2):
    - Descriptive: "there was no between-group difference at 24 h (16 [30%] vs 26 [49%]; p=0·58; figure 3D)." (Results, paragraph beginning “Time to conventional attack treatment use or worsening”) vs "Within 24 h (exploratory endpoint) | .. | .. | 0.058†" (Table 2, proportion of attacks with conventional treatment or worsened PGI-S). The Results and Table 2 assign p=0·58 and p=0.058, respectively, to the same 24-hour exploratory composite comparison. → Conclusion holds
    - Descriptive: "Five (7%) of 68 participants had any drug-related treatment-emergent adverse event" (Results, safety paragraph; Table 3 (any drug-related TEAE, overall)) vs "Any drug-related treatment-emergent adverse event" (Table 3, row 'Any drug-related treatment-emergent adverse event', Overall column (7 [10%])). The prose gives five participants (7%), matching Table 3 part 1, while Table 3 gives seven participants (10%) overall. → Conclusion holds
- **Reporting and transparency:** Clean. Ethics approval, consent, registration, sponsor involvement, conflicts of interest, and conditional data sharing are declared. Unavailable supporting materials limit verification but do not independently establish a conduct concern.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared
- **Reference integrity:** Clean. 38 of 38 checkable references verified
  - 44 references in manuscript
  - 6 have no canonical index record — counted, but not index-checkable
  - 2 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-03